Owl biomedical, Inc.
Miltenyi Biotec acquired Owl biomedical in February 2013, in 2023 it was fully integrated into Miltenyi Biotec, Inc. At the former site in Santa Barbara exclusive cell sorting micro-electro mechanical systems (MEMS) technology for application in cell therapy, cancer diagnostics, and basic research were produced.
Milestones
- 2009 – First Nanosorter® (precursor to MACSQuant Tyto Cell Sorter) sorts cells via microchip & fluorescent labeling
- 2011 – Founding of Owl biomedical
- 2011 – First Nanosorter installed at Fred Hutch Cancer Research Center
- 2013 – Owl biomedical acquired by Miltenyi Biotec
- 2014 – First clinical trial started at MDAnderson with the Nanosorter for Ag+ T cell therapy for melanoma
- 2015 – First patient infused with micro-fluidically sorted cells from the Nanosorter
- 2016 – MACSQuant Tyto Cell Sorter approved for clinical trials at MDAnderson for Ag+ T cell therapy for melanoma
- 2016 – First patient infused cells sorted with MACSQuant Tyto Cell Sorter
- 2019 – First clinical trial performed in Japan with MACSQuant Tyto Cell Sorter for Parkinson’s treatment
- 2019 – First MACSQuant Tyto Cell Sorter installed in a BSL3 at the NIH
- 2021 – The 200th MACSQuant Tyto Cell Sorter shipped
- 2022 – Manufacture of the 1,000,000th microchip
- 2023 – Full integration of Owl biomedical, Inc. into Miltenyi Biotec, Inc.
You have previously chosen International as your location.
What do you want to do?